drugset
drugset / Trial / NCT03092232

Single Dose Study to Assess the Safety, Tolerability and Pharmacokinetics(PK) of PF-06865571

NCT03092232 ↗

Phase 1 Completed 17 enrolled Pfizer
RandomizedCrossoverTriple-blindBasic science

Summary

The current study is the first clinical trial proposed with PF-06865571. It is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) following administration of single doses of PF-06865571 to healthy adult subjects.

Timeline

Start
2017-03-16
Primary completion
2017-07-13
Completion
2017-07-17

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-06865571 Small molecule 5 mg Oral
Subject PF-06865571 Small molecule 15 mg Oral
Subject PF-06865571 Small molecule 50 mg Oral
Subject PF-06865571 Small molecule 150 mg Oral
Subject PF-06865571 Small molecule 500 mg Oral
Subject PF-06865571 Small molecule 1000 mg Oral
Subject PF-06865571 Small molecule 2000 mg Oral

Indications

No indication recorded.